Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.
about
Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methodsThe diagnosis of primary biliary cirrhosisOverdiagnosis and overtreatment of prostate cancerLong-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimatesEffect of intra-observer variation in prostate volume measurement on prostate-specific antigen density calculations among prostate cancer active surveillance participants.Calibrating disease progression models using population data: a critical precursor to policy development in cancer controlLatent class cluster analysis to understand heterogeneity in prostate cancer treatment utilities.Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.Quality-of-life effects of prostate-specific antigen screening.Quantifying the role of PSA screening in the US prostate cancer mortality decline.What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models.Lung cancer screening with CTEmpirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.Doctors' approaches to PSA testing and overdiagnosis in primary healthcare: a qualitative study.Automated multiplexed ECL Immunoarrays for cancer biomarker proteins.Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection BiomarkersReducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC.Risk stratification of men choosing surveillance for low risk prostate cancer.3D-printed supercapacitor-powered electrochemiluminescent protein immunoarrayA System Dynamics Model of Serum Prostate-Specific Antigen Screening for Prostate Cancer.Overdiagnosis of prostate cancer.Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer ScreeningInfluence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening.Evaluation of new technologies for cancer control based on population trends in disease incidence and mortality.Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening.Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and contextProstate-cancer mortality in the USA and UK in 1975-2004: an ecological study.Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancerGenome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer.Multi-state Markov models in cancer screening evaluation: a brief review and case study.The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: which markers matter and how should they be used?Missteps in Current Estimates of Cancer Overdiagnosis.A descriptive study of prostate cancer mortality in the state of São Paulo, from 1980 to 2007.Cost-effectiveness of MR Imaging-guided Strategies for Detection of Prostate Cancer in Biopsy-Naive Men.Alcohol consumption and rates of cancer screening: Is cancer risk overestimated?Response: Reading between the lines of cancer screening trials: using modeling to understand the evidence.High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancerPSA screening and deaths from prostate cancer after diagnosis--a population based analysis.Personalized prostate cancer screening: improving PSA tests with genomic information.Active surveillance for prostate cancer: an Australian experience.
P2860
Q26824867-CFFD35DE-BDF5-4C91-9E70-B48AF6F6DF4AQ26829493-B1463315-8050-4364-9EEC-8F3CA0486EA7Q26859596-A0659805-F109-45BD-8964-1FADEA1EAD64Q28251617-07572A8B-5676-4B52-BEA5-80588E900ABAQ30453835-9718AA75-4E2B-4118-8FFB-120EAA7EE07FQ30496883-333C95C5-7646-4F56-80B9-38B78FF90981Q30920896-0C88309D-79C4-4795-A458-8405F0598859Q33835863-72FF2608-5D00-491D-B1D4-72A78ADE9FD2Q34294102-6160F1A9-4977-41E7-8CDC-C625B2CE25BBQ34720042-E86AC224-F6C1-4648-B54C-2D2C66208268Q34963971-6BC61793-CB01-4B8C-A204-A5B930BD6EA7Q35018681-963F22F5-5953-43F6-97F2-978E3966C5C6Q35089983-E39EDBD0-78D7-49DD-BD7A-BA97D9766113Q35204021-23B9CC4A-C3BF-4EB9-BE45-695758F10FE1Q35623945-D59946BA-6B78-44BE-924C-A5DAE0B99FE5Q36123823-5BA5DDF4-72D3-428C-A1D4-BA7C0FEC0B50Q36295073-AC7008C1-6917-4B8D-BE37-CA6B483F43ADQ36328870-677E4095-E937-4BD0-95A0-69D11CFB6FBBQ36355513-4AC1234E-0111-4EF6-9C1D-7431EA0990E7Q36493623-993D5E39-5A27-4180-91CE-E34E6DAFEEE6Q36520508-0D100864-9B4A-4248-8632-F2C38297E20FQ36706929-EFBF18CB-84F1-47F4-9BCC-B2B9A17D3437Q37070417-D0E977B9-79E3-432D-9EA1-86BB64EF5C74Q37106776-2A297D97-800B-4085-ADB7-40CAB8BCA4A4Q37160706-228498AC-CA50-455E-9063-24FAC838AFBEQ37288832-03ED814E-7989-4683-A648-7FCCD48431CDQ37384669-1D4B24DD-F87D-448E-83AF-37CD8760F798Q37457676-99B6AC36-0A12-43DA-A916-71BFD1886DE8Q37622580-AD5C5126-437A-4FE1-9F59-B2A812B208BAQ37709746-1AE11BD2-BB9B-4872-BAA8-04E7B53970F4Q38211603-B287E47D-40A9-42D6-BB37-A6BB4EAD0197Q39022692-CD82D7ED-012F-42E9-A5E4-2830A2B8A54BQ40114575-113B84A0-D99A-4B9E-9D44-2978D9CF6145Q40198300-C1B624C2-9121-4E75-806A-741BF958990CQ40293353-2A45D3E2-EA43-4E10-B269-921F6A7DBF7EQ41437748-84BD6E15-8F04-471E-BE57-DDB9E09F39DCQ42539779-C7C1D9AF-252F-45E0-A140-D97FDA034E1DQ44497157-A5BD1C69-2F9B-459D-A7D1-3698CC152BD7Q45978317-BF24FDA4-EA19-4AC7-B002-E698CEE1C820Q45981263-40F3E094-7234-4168-8DD9-17F81140C866
P2860
Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Estimating lead time and overd ...... state cancer incidence trends.
@en
Estimating lead time and overd ...... state cancer incidence trends.
@nl
type
label
Estimating lead time and overd ...... state cancer incidence trends.
@en
Estimating lead time and overd ...... state cancer incidence trends.
@nl
prefLabel
Estimating lead time and overd ...... state cancer incidence trends.
@en
Estimating lead time and overd ...... state cancer incidence trends.
@nl
P2093
P2860
P1433
P1476
Estimating lead time and overd ...... state cancer incidence trends.
@en
P2093
Donatello Telesca
Roman Gulati
Ruth Etzioni
P2860
P356
10.1111/J.1541-0420.2007.00825.X
P407
P577
2007-05-14T00:00:00Z